In this edition: Checkpoint inhibitors: pregnancy-related outcomes; JAK inhibitors: risk minimisation / dosage individualisation; COVID-19 vaccines: myocarditis in elderly patients / adverse reactions after vaccination with bivalent vaccines; Haemovigilance: incorrect blood component transfused and near misses
In the 7th issue of the Swissmedic magazine “Visible”, we explain the requirements a medicinal product has to meet before it is authorised, Swissmedic's strategic objectives for the next four years, and much more. We hope you enjoy reading it!
